Physician Notification for Aortic Stenosis
(DETECT AS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if sending doctors alerts about patients with severe heart valve problems can improve treatment and reduce care differences among different groups.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is the Physician Notification for Aortic Stenosis generally safe for humans?
How does the Physician Notification for Aortic Stenosis treatment differ from other treatments for this condition?
The Physician Notification for Aortic Stenosis treatment is unique because it involves using electronic health record (EHR) alerts to notify physicians about patient conditions, which can improve timely follow-up and management compared to traditional methods that may not provide real-time updates.36789
What data supports the effectiveness of this treatment for aortic stenosis?
Research shows that electronic alerts and notifications can improve communication and coordination among healthcare providers. For example, automated systems have been effective in ensuring timely follow-up care and improving awareness of patient conditions, which suggests that similar notification systems could help manage aortic stenosis by keeping physicians informed and facilitating better care coordination.37101112
Are You a Good Fit for This Trial?
This trial is for patients with severe aortic stenosis, where the opening of their aortic valve is less than or equal to 1.0cm2. It's not for those who already have artificial (bioprosthetic or mechanical) valves in place.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Providers in the intervention group receive electronic notifications about patients with severe aortic stenosis, highlighting management guidelines.
Follow-up
Participants are monitored for AVR utilization, mortality, heart failure hospitalization, and other secondary outcomes.
What Are the Treatments Tested in This Trial?
Interventions
- Physician Notification Letter
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Edwards Lifesciences
Industry Sponsor
Todd Brinton
Edwards Lifesciences
Chief Medical Officer since 2023
MD from Stanford University
Bernard Zovighian
Edwards Lifesciences
Chief Executive Officer since 2023
MBA from INSEAD